- Previous Close
2.9700 - Open
3.0300 - Bid 2.9700 x --
- Ask 2.9800 x --
- Day's Range
2.9500 - 3.0200 - 52 Week Range
2.7100 - 4.3200 - Volume
12,187,800 - Avg. Volume
19,323,811 - Market Cap (intraday)
3.511B - Beta (5Y Monthly) 0.31
- PE Ratio (TTM)
24.75 - EPS (TTM)
0.1200 - Earnings Date --
- Forward Dividend & Yield 0.02 (0.71%)
- Ex-Dividend Date Jul 10, 2024
- 1y Target Est
--
Huaren Pharmaceutical Co., Ltd. produces and sells non-PVC soft bag infusions in China. It offers doxofylline, levofloxacin hydrochloride, compound potassium hydrogen phosphate, and caffeine citrate, sodium chloride, glucose, glucose sodium potassium, chloride, compound sodium chloride, sodium lactate ringer, compound electrolyte, and sterilized water injections. The company also provides therapeutic infusion products for blood volume expansion, hemostasis, nervous and circulatory systems, anti-infection, anti-hepatitis, hepatitis adjuvant, anti-tumor, and sugar metabolism; and medical instruments, such as disposable incision retractors, disposable cannula puncture devices disposable specimen extractors, abdominal suction tubes, incision retractor protectors, iodine protective caps, slip pads, respiratory oscillation expectoration machines, protective mask cup types, protective and foldable disposable masks, and medical protective masks. In addition, it offers pharmaceutical packaging materials, including rubber stopper, carton, and membrane; rinsing fluid and API series products; and food and beverage, and medical skin care products. The company was founded in 1998 and is based in Qingdao, China.
www.qdhuaren.com2,681
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 300110.SZ
View MorePerformance Overview: 300110.SZ
Trailing total returns as of 4/18/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 300110.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 300110.SZ
View MoreValuation Measures
Market Cap
3.51B
Enterprise Value
4.98B
Trailing P/E
23.99
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.35
Price/Book (mrq)
1.27
Enterprise Value/Revenue
3.34
Enterprise Value/EBITDA
20.54
Financial Highlights
Profitability and Income Statement
Profit Margin
9.81%
Return on Assets (ttm)
3.80%
Return on Equity (ttm)
5.52%
Revenue (ttm)
1.49B
Net Income Avi to Common (ttm)
146.51M
Diluted EPS (ttm)
0.1200
Balance Sheet and Cash Flow
Total Cash (mrq)
120.1M
Total Debt/Equity (mrq)
56.09%
Levered Free Cash Flow (ttm)
-238.62M